International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN. 

Utility of lipid ratios as a cardiometabolic risk assessor of hypertensive heart disease patients with artrial fibrillation in a secondary health institution in Benin City, Nigeria

    , , ,

Author Affiliations

  • 1Department of Chemical Pathology, Edo State University Uzairue; ORCID: 0000-0001-7638-6040, Nigeria
  • 2Department of Chemical Pathology, University of Benin, Benin City, Nigeria
  • 3Dept. of Chemical Pathology, Alex Ekweme Federal University Teaching Hospital, Abakaliki, Nigeria
  • 4Dept of Chemical Pathology, Delta State University, Abraka, Nigeria

Res. J. Family, Community and Consumer Sci., Volume 13, Issue (1), Pages 1-8, January,27 (2025)

Abstract

Atrial fibrillation is the most common cardiac arrhythmia worldwide, and risk factors for the condition include ageing, obesity, hypertension, diabetes mellitus, and diabetes. The control group included at least one male participant for every two participants, according to the results, but 47.2% of the subject group had female participants. At a secondary health facility in Benin City, Nigeria, this study attempts to test the usefulness of lipid ratios as a cardiometabolic risk assessor in patients with hypertensive heart disease and atrial fibrillation. There are 100 participants in the study: 53 patients with atrial fibrillation and hypertensive heart illness and 47 non-hypertensive people who serve as the control group. Cardiometabolic risk variables were assessed by the analysis of lipid profiles, blood pressure readings, and different lipid ratios. Results whoed that The study group's mean age was 59.5 years, in contrast to the control group's mean age of 58.3 years. Total cholesterol in the control (159.13 mg/dl) significantly differed from the subject group (216.79 mg/dl) (p<0.05). Antherogenic index plasma (AIP), non-HDL cholesterol, and antherogenic coefficent all increased significantly in the subject group. The results imply that lipid profiles and ratios are crucial for determining cardiometabolic risk in this patient.

References

  1. Harrison S.L, Lane D.A, Banach M, Mastej M, Kasperczyk S, Jóźwiak J.J, Lip G.Y.H (2020)., Lipid levels, atrial fibrillation and the impact of age: Results from the LIPIDOGRAM2015 study., Atherosclerosis, 312, 16-22 4
  2. Li, C., Ford, E. S., Mokdad, A. H., Balluz, L. S., Brown, D. W., & Giles, W. H. (2008)., Clustering of cardiovascular disease risk factors and health‐related quality of life among US adults., Value in Health, 11(4), 689-699.
  3. Li, X., Gao, L., Wang, Z., Guan, B., Guan, X., Wang, B., ... & Xia, Y. (2018)., Lipid profile and incidence of atrial fibrillation: a prospective cohort study in China., Clinical cardiology, 41(3), 314-320.
  4. Mourtzinis, G., Kahan, T., Boström, K. B., Schiöler, L., Wallin, L. C., Hjerpe, P., ... & Manhem, K. (2018)., Relation between lipid profile and new-onset atrial fibrillation in patients with systemic hypertension (from the Swedish Primary Care Cardiovascular Database [SPCCD])., The American journal of cardiology, 122(1), 102-107.
  5. Millán, J., Pintó, X., Muñoz, A., Zúñiga, M., Rubiés-Prat, J., Pallardo, L. F., ... & Pedro-Botet, J. (2009)., Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention., Vascular health and risk management, 757-765.
  6. Prabhu, S., Voskoboinik, A., Kaye, D. M., & Kistler, P. M. (2017)., Atrial fibrillation and heart failure—cause or effect?., Heart, Lung and Circulation, 26(9), 967-974.
  7. Stegmann, C., & Hindricks, G. (2019)., Atrial fibrillation in heart failure—diagnostic, therapeutic, and prognostic relevance., Current Heart Failure Reports, 16, 108-115.
  8. Carlisle, M. A., Fudim, M., DeVore, A. D., & Piccini, J. P. (2019)., Heart failure and atrial fibrillation, like fire and fury., JACC: Heart Failure, 7(6), 447-456.
  9. Neuberger, H. R., Mewis, C., van Veldhuisen, D. J., Schotten, U., van Gelder, I. C., Allessie, M. A., & Böhm, M. (2007)., Management of atrial fibrillation in patients with heart failure., European heart journal, 28(21), 2568-2577.
  10. UK, G. Y. L., De Caterina, R., UK, I. S., Atar, D., Hohnloser, S. H., Hindricks, G., & UK, P. K. (2012)., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation., European Heart Journal, 33, 2719-2747.
  11. Dokainish, H., Teo, K., Zhu, J., Roy, A., AlHabib, K. F., ElSayed, A., ... & Inter-Chf Investigators. (2016)., Heart failure in Africa, Asia, the Middle East and South America: the INTER-CHF study., International Journal of Cardiology, 204, 133-141.
  12. Dokainish, H., Teo, K., Zhu, J., Roy, A., AlHabib, K. F., ElSayed, A., ... & INTER-CHF Investigators (2016)., Heart failure in Africa, Asia, the Middle East and South America: the INTER-CHF study., International Journal of Cardiology, 204, 133-141.
  13. American College of Cardiology Foundation/American Heart Association Task Force (2011)., ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology foundation/American heart association task force on practice guidelines., Circulation, 123(10), e269-e367.
  14. Akintunde, A. A., Akinlade, O. M., Egbewale, B. E., & Opadijo, O. G. (2021)., Iron deficiency anemia in Nigerians with heart failure (IDAN-HF): therapeutic efficacy of iron replacement: an interventional study., Nigerian Journal of Clinical Practice, 24(1), 21-27.
  15. Wang, T. J., Larson, M. G., Levy, D., Vasan, R. S., Leip, E. P., Wolf, P. A., ... & Benjamin, E. J. (2003)., Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study., Circulation, 107(23), 2920-2925.
  16. Lubitz, S. A., Benjamin, E. J., & Ellinor, P. T. (2010)., Atrial fibrillation in congestive heart failure., Heart failure clinics, 6(2), 187-200.
  17. McIntyre, R. S., Danilewitz, M., Liauw, S. S., Kemp, D. E., Nguyen, H. T., Kahn, L. S., ... & Taylor, V. H. (2010)., Bipolar disorder and metabolic syndrome: an international perspective., Journal of affective disorders, 126(3), 366-387.
  18. Johannessen, L., Strudsholm, U., Foldager, L., & Munk-Jørgensen, P. (2006)., Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia., Journal of affective disorders, 95(1-3), 13-17.
  19. Colantonio, L. D., Bittner, V., Reynolds, K., Levitan, E. B., Rosenson, R. S., Banach, M., ... & Muntner, P. (2016)., Association of serum lipids and coronary heart disease in contemporary observational studies., Circulation, 133(3), 256-264.
  20. Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne C.M, Psaty B.M, Sundström J, Ridker P.M, Nagel D, Gillum R.F, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart R.P, Assmann G, D’Agostino R.B, Sr., Dagenais G.R, Cooper J.A, Kromhout D, Onat A, Tipping R.W, Gómez-de-la-Cámara A, Rosengren A, Sutherland S.E, Gallacher J, Fowkes F.G, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema J.W, Simons L.A, Sandhu M, Wareham N.J, Khaw K.T, Kauhanen J, Salonen J.T, Howard W.J, Nordestgaard B.G, Wood A.M, Thompson S.G, Boekholdt S.M, Sattar N, Packard C, Gudnason V, Danesh J (2012)., Lipid related markers and cardiovascular disease prediction., Jama,; 307, 2499-2506 3
  21. World Health Organization (2021)., Hypertension., [Last accessed: 25 August 2021]. Geneva, Switzerland.
  22. Adeke, A. S., Chori, B. S., Neupane, D., Sharman, J. E., & Odili, A. N. (2024)., Socio-demographic and lifestyle factors associated with hypertension in Nigeria: results from a country-wide survey., Journal of human hypertension, 38(4), 365-370.
  23. Karimi, F., Rayani, M., Akbarzade, S., Tahmasebi, R., Khakzade, M., & Arab, J. (2000)., The prevalence of hyperlipidemia in persons over 19 years of Bushehr in 1378., Iran South Med J, 3(2), 98-106.
  24. Nadimi, A. E., & Jafar Ahmadi, J. A. (2004)., Lipid abnormalities in urban population of Rafsanjan (Rafsanjan coronary risk factors study phase 1).,
  25. Gutierrez, J., Ramirez, G., Rundek, T., & Sacco, R. L. (2012)., Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis., Archives of internal medicine, 172(12), 909-919.
  26. Afilalo, J., Majdan, A. A., & Eisenberg, M. J. (2007)., Intensive stat in therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials., Heart, 93(8), 914-921.